GlassScriptPhysician profile
Tzvi D Braver
NPI 1083807176
$2,576.47
in general payments reported to CMS, 2019-2025
28 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $112 · 2021: $179 · 2022: $357 · 2023: $637 · 2024: $746 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.16 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $292.24 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $252.27 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $195.17 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $131.33 | 2022-2024 | Rexulti |
| Exact Sciences Corporation | $116.61 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $104.28 | 2023-2024 | Airsupra |
| Teladoc Health, INC. | $100.00 | 2022 | |
| Axsome Therapeutics, INC. | $88.32 | 2022-2024 | Auvelity |
| Merck Sharp & Dohme LLC | $88.26 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Novartis Pharmaceuticals Corporation | $81.30 | 2020-2024 | |
| Glaxosmithkline, LLC. | $75.84 | 2021-2025 | Bexsero, Arexvy, Shingrix |
| Phadia US INC. | $63.56 | 2019-2021 | |
| Shire North American Group INC | $44.12 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $39.38 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.54 | 2020 | |
| Nestle Healthcare Nutrition INC. | $30.31 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.90 | 2021 | |
| Scynexis, INC. | $29.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.00 | 2020 | |
| Amgen INC. | $18.50 | 2025 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $14.52 | 2024 | Voquezna |
| Kaleo, INC. | $14.32 | 2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $14.05 | 2023 | Trintellix |
| Dexcom, INC. | $13.22 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $12.97 | 2022 | |
| Redhill Biopharma INC. | $12.56 | 2020 | |
| Abbott Laboratories | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tzvi Braver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.